Description
Sytrax-TZ 1125 Injection is a powerful combination of Ceftriaxone (third-generation cephalosporin) and Tazobactam (β-lactamase inhibitor), designed to deliver enhanced antibacterial activity against resistant organisms. It is widely used in the treatment of moderate to severe bacterial infections in hospital and clinical settings.
Composition (Typical)
- Ceftriaxone Sodium IP – 1000 mg
- Tazobactam Sodium IP – 125 mg
- Total: 1125 mg
Mechanism of Action
- Ceftriaxone: Inhibits bacterial cell wall synthesis, leading to bacterial cell death
- Tazobactam: Inhibits β-lactamase enzymes, preventing antibiotic degradation and enhancing efficacy against resistant strains
Indications
- Lower respiratory tract infections (including pneumonia)
- Urinary tract infections (UTIs)
- Intra-abdominal infections
- Skin & soft tissue infections
- Bone & joint infections
- Septicemia
- Gynecological infections
Dosage & Administration
- Administer via Intramuscular (IM) or Intravenous (IV) route
- Reconstitute with recommended diluent prior to use
- Dosage should be as directed by the physician
Key Benefits
- Advanced β-lactamase inhibitor combination
- Broader coverage against resistant pathogens
- High efficacy in serious and complicated infections
- Suitable for empirical therapy in hospital settings
Precautions
- Contraindicated in patients with cephalosporin hypersensitivity
- Use cautiously in renal/hepatic impairment
- Monitor for superinfection and antibiotic resistance with prolonged use
Storage
- Store below 25°C
- Protect from light and moisture
- Use immediately after reconstitution
Pack Details
- Vial containing 1125 mg dry powder for injection
